`Date Filed: November 17, 2016
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`AMERIGEN PHARMACEUTICALS LIMITED
`Petitioner,
`
`v.
`
`JANSSEN ONCOLOGY, INC.,
`Patent Owner.
`
`________________
`
`Case IPR2016-002861
`Patent 8,822,438 B2
`
`________________
`
`
`JANSSEN ONCOLOGY, INC.’S MOTION FOR PRO HAC VICE
`ADMISSION OF ALYSSA B. MONSEN
`
`
`
`
`
`
`
`
`
`
`1 Case IPR2016-01317 has been joined with this proceeding.
`
`
`
`
`
`
`
`IPR2016-00286
`Patent No. 8,822,438 B2
`
`
`
`Pursuant to 37 C.F.R. § 42.10(c) and the Board’s December 10, 2015 Notice
`
`of Filing Date Accorded to Petition and Time for Filing Patent Owner Preliminary
`
`Response (Paper 4), Patent Owner Janssen Oncology, Inc. (“Janssen”) respectfully
`
`requests the pro hac vice admission of attorney Alyssa B. Monsen in this
`
`proceeding. Patent Owner has conferred with counsel for Petitioners, and
`
`Petitioners do not oppose this motion.
`
`I.
`
`Statement of Facts Showing Good Cause for the Board to Recognize
`Alyssa B. Monsen Pro Hac Vice in this Proceeding
`
`The Board may recognize counsel pro hac vice during an inter partes review
`
`proceeding upon a showing of good cause, “subject to the condition that lead
`
`counsel be a registered practitioner and to any other conditions as the Board may
`
`impose.” 37 C.F.R. § 42.10(c). For example, “where the lead counsel is a
`
`registered practitioner, a motion to appear pro hac vice by counsel who is not a
`
`registered practitioner may be granted upon showing that counsel is an experienced
`
`litigating attorney and has an established familiarity with the subject matter at issue
`
`in the proceeding.” Id.
`
`As set forth below and in the accompanying Declaration of Alyssa B.
`
`Monsen in Support of Motion to Appear Pro Hac Vice (“Monsen Decl.,” Exhibit
`
`2120), the facts here establish good cause for the Board to recognize Alyssa B.
`
`Monsen pro hac vice in this proceeding.
`
`
`
`2
`
`
`
`IPR2016-00286
`Patent No. 8,822,438 B2
`
`1. Lead Counsel, Dianne Elderkin, is a registered practitioner (Reg. No.
`
`28,598).
`
`2. Ms. Monsen is a member in good standing of the State Bar of New
`
`York (Bar No. 5082326). See Exhibit 2120, ¶ 2.
`
`3. Ms. Monsen has never been suspended or disbarred from practice
`
`before any court or administrative body. See Exhibit 2120, ¶ 3.
`
`4. None of Ms. Monsen’s applications for admission to practice before
`
`any court or administrative body have ever been denied. See Exhibit 2120, ¶ 4.
`
`5. Ms. Monsen has not been sanctioned nor has she had a contempt
`
`citation imposed on her by any court or administrative body. See Exhibit 2120, ¶
`
`5.
`
`6. Ms. Monsen has declared that she has read and will comply with the
`
`Office Patent Trial Practice Guide and the Board’s Rules of Practice for Trial set
`
`forth in part 42 of 37 C.F.R. See Exhibit 2120, ¶ 6.
`
`7. Ms. Monsen has acknowledged and agrees that she will be subject to
`
`the USPTO Rules of Professional Conduct set forth in 37 C.F.R. § 11.101 et. seq.
`
`and disciplinary jurisdiction under 37 C.F.R. § 11.19(a). See Exhibit 2120, ¶ 7.
`
`8. Ms. Monsen has not applied to appear pro hac vice before the Patent
`
`Trial and Appeal Board in the last three years. See Exhibit 2120, ¶ 8.
`
`
`
`3
`
`
`
`IPR2016-00286
`Patent No. 8,822,438 B2
`
`9. Ms. Monsen has been a practicing attorney for almost 5 years and has
`
`been involved in several patent cases. She is presently counsel for Janssen in a
`
`pending patent litigation involving the patent under review in this proceeding, U.S.
`
`Patent No. 8,822,438 (the “’438 patent”). This case is captioned BTG Int’l Ltd., et
`
`al. v. Actavis Labs. FL, Inc., et al., C.A. No. 2:15-cv-05909-KM-JBC (D.N.J.). As
`
`part of this litigation, Ms. Monsen has studied and analyzed the ’438 patent and
`
`has become very familiar with its subject matter. She is also familiar with prior art
`
`asserted in this IPR proceeding, conception and reduction to practice of the
`
`inventions claimed in the ’438 patent, and claim construction of various claim
`
`terms. See Exhibit 2120, ¶ 9.
`
`In view of Ms. Monsen’s knowledge of the subject matter at issue in this
`
`proceeding, and in view of the interrelatedness of this proceeding and the district
`
`court litigation mentioned above, Janssen has a significant need for Ms. Monsen’s
`
`pro hac vice admission and her involvement in the continued prosecution of this
`
`proceeding. In addition, pro hac vice admission of Ms. Monsen will enable
`
`Janssen to avoid unnecessary expense and duplication of work between this
`
`proceeding and the related district court litigations. See 77 Fed. Reg. 48,612,
`
`48,661 (Aug. 14, 2012) (Office’s comment on final rule discussing concerns about
`
`efficiency and costs where an entity has already engaged counsel for parallel
`
`district court litigation).
`
`
`
`4
`
`
`
`IPR2016-00286
`Patent No. 8,822,438 B2
`
`II.
`
`Conclusion
`
`For the foregoing reasons, Patent Owner Janssen respectfully requests that
`
`the Board admit Ms. Monsen pro hac vice in this proceeding.
`
`Date: November 17, 2016
`
`
`
`
`
`Respectfully submitted,
`
`
`
`/Dianne B. Elderkin/
`Dianne B. Elderkin
`Registration No. 28,598
`Counsel for Patent Owner
`
`
`
`
`
`
`
`5
`
`
`
`IPR2016-00286
`Patent No. 8,822,438 B2
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing Janssen
`
`Oncology, Inc.’s Motion for Pro Hac Vice Admission of Alyssa B. Monsen was
`
`served on counsel of record on November 17, 2016 by filing this document
`
`through the End-to-End System, as well as delivering a copy via electronic mail to
`
`counsel of record for the Petitioners at the following addresses:
`
`William Hare - bill@miplaw.com
`Gabriela Materassi - materassi@miplaw.com
`
`Teresa Stanek Rea - TRea@Crowell.com
`Shannon M. Lentz - SLentz@Crowell.com
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`By: /Dianne B. Elderkin/
`Dianne B. Elderkin
`Registration No. 28,598
`Counsel for Patent Owner
`
`6
`
`
`
`Date: November 17, 2016